Ipilimumab and Local Radiation for Selected Solid Tumors

PRIMARY OBJECTIVES: 1\. To assess the safety of combining intratumoral anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immunotherapy with local radiation therapy in patients with melanoma, non-Hodgkin lymphoma, and colorectal carcinoma with a monotherapy ipilimumab safety lead-in. SECONDARY OBJECTIVES: 1. To assess the induction of an anti-tumor immune responses using laboratory correlative studies. 2. To determine tumor response rates and duration of response at unirradiated tumor sites in patients with advanced malignancies. 3. To identify putative immunologic biomarkers of tumor response. OUTLINE: This is a phase I safety study of ipilimumab monotherapy, followed by a phase 2 study. Only a few subjects participated in the phase 1 portion of this study. The phase 2 treatment-escalation portion of this study (ipilimumab plus radiation combination therapy) was not conducted. Patients receive ipilimumab intratumorally on day 1 and undergo local radiation therapy within 48 hours for at least 3 fractions. After completion of study treatment, patients are followed up at 4 and 8 weeks, and then every 24 weeks for 5 years.